Suncoast Equity Management increased its holdings in shares of STERIS plc (NYSE:STE – Free Report) by 5.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,255 shares of the medical equipment provider’s stock after acquiring an additional 162 shares during the quarter. Suncoast Equity Management’s holdings in STERIS were worth $789,000 at the end of the most recent quarter.
A number of other large investors have also recently bought and sold shares of STE. Massachusetts Financial Services Co. MA raised its position in shares of STERIS by 13.7% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 6,442,805 shares of the medical equipment provider’s stock worth $1,414,453,000 after purchasing an additional 778,613 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in STERIS by 7.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,738,630 shares of the medical equipment provider’s stock valued at $390,880,000 after buying an additional 120,616 shares during the last quarter. Sustainable Growth Advisers LP lifted its stake in STERIS by 23.5% in the first quarter. Sustainable Growth Advisers LP now owns 1,485,578 shares of the medical equipment provider’s stock valued at $333,988,000 after buying an additional 282,387 shares during the last quarter. Impax Asset Management Group plc boosted its holdings in shares of STERIS by 29.7% during the second quarter. Impax Asset Management Group plc now owns 1,150,517 shares of the medical equipment provider’s stock valued at $251,663,000 after acquiring an additional 263,383 shares during the period. Finally, Principal Financial Group Inc. grew its position in shares of STERIS by 0.9% during the second quarter. Principal Financial Group Inc. now owns 1,017,888 shares of the medical equipment provider’s stock worth $223,467,000 after acquiring an additional 8,601 shares during the last quarter. Institutional investors own 94.69% of the company’s stock.
STERIS Price Performance
Shares of STE traded down $1.83 during midday trading on Monday, reaching $223.82. The stock had a trading volume of 105,148 shares, compared to its average volume of 471,829. The firm’s 50 day moving average price is $235.66 and its 200-day moving average price is $226.07. STERIS plc has a 52 week low of $195.47 and a 52 week high of $248.24. The company has a market capitalization of $22.07 billion, a P/E ratio of 55.99 and a beta of 0.84. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.33 and a quick ratio of 1.49.
STERIS Increases Dividend
The business also recently disclosed a quarterly dividend, which was paid on Friday, September 20th. Stockholders of record on Thursday, September 5th were paid a dividend of $0.57 per share. The ex-dividend date of this dividend was Thursday, September 5th. This is a positive change from STERIS’s previous quarterly dividend of $0.52. This represents a $2.28 annualized dividend and a dividend yield of 1.02%. STERIS’s dividend payout ratio (DPR) is currently 56.58%.
Analysts Set New Price Targets
STE has been the subject of a number of analyst reports. Needham & Company LLC reissued a “hold” rating on shares of STERIS in a research note on Thursday, August 8th. Stephens reissued an “overweight” rating and issued a $260.00 price objective on shares of STERIS in a report on Wednesday, August 7th. JMP Securities reaffirmed a “market outperform” rating and set a $265.00 target price on shares of STERIS in a research note on Wednesday, August 7th. KeyCorp increased their price target on STERIS from $255.00 to $265.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 3rd. Finally, StockNews.com upgraded shares of STERIS from a “hold” rating to a “buy” rating in a research note on Tuesday, August 13th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $246.00.
Read Our Latest Research Report on STE
Insider Transactions at STERIS
In related news, Director Christopher S. Holland sold 473 shares of STERIS stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $239.68, for a total value of $113,368.64. Following the transaction, the director now owns 582 shares of the company’s stock, valued at approximately $139,493.76. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, CFO Michael J. Tokich sold 23,332 shares of the company’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $247.00, for a total transaction of $5,763,004.00. Following the transaction, the chief financial officer now directly owns 42,930 shares of the company’s stock, valued at approximately $10,603,710. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Christopher S. Holland sold 473 shares of the firm’s stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $239.68, for a total value of $113,368.64. Following the sale, the director now owns 582 shares of the company’s stock, valued at $139,493.76. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.14% of the stock is owned by insiders.
About STERIS
STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.
Read More
- Five stocks we like better than STERIS
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Analysts Predict New Highs for Cybersecurity Stock by Christmas
- What is a Death Cross in Stocks?
- Nuclear Power Reaches Critical Mass: Top Stocks to Watch Now
- How to Use the MarketBeat Excel Dividend Calculator
- 2 Energy Stocks Surging on Billion-Dollar DOE Loan Commitments
Want to see what other hedge funds are holding STE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for STERIS plc (NYSE:STE – Free Report).
Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.